Bipolar II Disorder Clinical Trial
Official title:
Psychotherapy for Bipolar II Depression, Pilot Study, Phase II
Purpose of this study is to examine the effectiveness of an experimental psychotherapy (talk therapy) for the treatment of bipolar II depression. The name of this psychotherapy is Interpersonal and Social Rhythm Therapy for Bipolar II Depression (IPSRT-BPII). Subjects will be randomly assigned to receive either IPSRT-BPII or the medication Seroquel (quetiapine) to manage their symptoms of bipolar II depression. Subjects will receive the assigned therapy for up to 20 weeks.
The proposed pilot study is an experimental design intended to investigate the preliminary efficacy of Interpersonal Social Rhythm Therapy for Bipolar II Depression (IPSRT-BPII). A total of 56 eligible subjects with a diagnosis of bipolar II disorder will be randomly assigned to one of two treatment groups : Seroquel (n=28) or IPSRT-BPII (n=28). Following baseline assessment, all participants will undergo up to 20 weeks of their assigned treatment. Patients assigned to IPSRT-BPII who fail to respond (at least 50% reduction in HRSD-25 scores and YMRS ≤ 10) by week 12 will have Seroquel added to IPSRT-BPII. Subjects who achieve remission (defined as 3 consecutive weeks where both HRSD-25 and YMRS scores average ≤ 7) and have participated in the trial for a minimum of 12 weeks will be moved into a continuation phase where they will receive maintenance treatment (bi-monthly therapy sessions and/or pharmacotherapy) until week 20. Patients who do not achieve remission by Week 20 will be discontinued from treatment and referred for follow-up care. All subjects (remitters and non-remitters) will be assessed at 20 weeks. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Recruiting |
NCT05340686 -
Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression
|
N/A | |
Completed |
NCT00761761 -
Sensoril(Ashwaganhda)for Bipolar Disorder
|
Phase 3 | |
Active, not recruiting |
NCT04561622 -
Emotional Proactive Processing in Bipolar Disorder
|
||
Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
Recruiting |
NCT06184581 -
Lithium Versus Lamotrigine in Bipolar Disorder, Type II
|
Phase 4 | |
Active, not recruiting |
NCT03484494 -
Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression
|
N/A | |
Recruiting |
NCT05400785 -
Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning
|
N/A | |
Completed |
NCT05340504 -
Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder
|
Phase 2 | |
Active, not recruiting |
NCT05249309 -
Naturalistic Study of Ketamine in the Treatment of Depression
|
||
Recruiting |
NCT04211428 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder
|
||
Completed |
NCT03822416 -
Treating Smokers With Mental Illness
|
Phase 2 | |
Completed |
NCT01588457 -
Sequential Multiple Assignment Treatment for Bipolar Disorder
|
Phase 4 | |
Completed |
NCT03156504 -
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
|
Phase 4 | |
Recruiting |
NCT05004896 -
Ketamine for Treatment-Resistant Bipolar Disorder
|
Phase 2 | |
Terminated |
NCT02491307 -
Ginger.io Behavioral Health Study
|
N/A | |
Recruiting |
NCT05427123 -
Children's Bipolar Network Treatment Trial I
|
||
Not yet recruiting |
NCT05705063 -
Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness
|
N/A | |
Recruiting |
NCT05065294 -
Psilocybin Therapy for Depression in Bipolar II Disorder
|
Phase 2 |